Boston Heart Lab Corp. completes a $10 million equity and options-based funding round.
Boston Heart Lab Corp. closed a $10 million funding round, according to a Securities & Exchange Commission filing.
The Framingham, Mass.-based heart disease tests began the sale of equity and options July 26.
According to thefiling, a total of 46 investors were involved in the round. The document names former Cequent Pharmaceuticals Inc. CEO and current Boston Heart Lab chairman Peter Parker as a director, while Jeff Crisan and Alice Limkakeng of Boston-based Bain Capital Ventures are also named as directors.
Boston Heart Lab’s CEO is Susan Hertzberg, a former Quest Diagnostics executive, according to itswebsite.
Creating value with cheap medical devices (Best of MedCitizens)
Kidney failure treatment firm raising $1M; search for $5M continues
House GOP wants to kill medical device tax, but are their arguments tenuous?
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
No comments yet.
Post a Comment